Get the Stockscreener App
24.63
0.74%
0.18
Pre-market:
24.65
0.02
+0.08%
Tango Therapeutics Inc stock is traded at $24.63, with a volume of 2.29M.
It is up +0.74% in the last 24 hours and up +0.49% over the past month.
Tango Therapeutics Inc is a biotechnology company. It is dedicated to discovering novel drug targets and delivering the next generation of precision medicine for the treatment of cancer. It is engaged in the business of discovering and developing precision oncology therapies. It is currently developing two MTA-cooperative PRMT5 inhibitors; TNG462 for non-CNS cancers, including pancreatic and lung cancer, and TNG456, a next-generation, brain-penetrant PRMT5 inhibitor, for CNS cancers, including GBM. Its pipeline products are PRMT5 and CoREST.
See More
Previous Close:
$24.45
Open:
$23.99
24h Volume:
2.29M
Relative Volume:
0.78
Market Cap:
$4.15B
Revenue:
$56.99M
Net Income/Loss:
$-107.23M
P/E Ratio:
-30.04
EPS:
-0.8199
Net Cash Flow:
$-142.55M
1W Performance:
+4.85%
1M Performance:
+0.49%
6M Performance:
+26.44%
1Y Performance:
+215.77%
1-Day Range:
$23.50
$24.82
1-Week Range:
$21.63
$25.92
52-Week Range:
$6.69
$34.39
Tango Therapeutics Inc Stock (TNGX) Company Profile
Name
Tango Therapeutics Inc
Sector
Industry
Phone
(857) 320-4900
Address
201 BROOKLINE AVENUE, BOSTON
Compare TNGX vs VRTX, REGN, MRNA, ARGX, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
TNGX
Tango Therapeutics Inc
|
24.63 | 4.15B | 56.99M | -107.23M | -142.55M | -0.8199 |
VRTX
Vertex Pharmaceuticals Inc
|
522.38 | 132.40B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
796.02 | 81.95B | 14.92B | 4.42B | 3.79B | 41.04 |
MRNA
Moderna Inc
|
194.82 | 77.78B | 2.23B | -3.19B | -1.60B | -8.1462 |
ARGX
Argen X Se Adr
|
962.22 | 60.20B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
199.86 | 42.84B | 742.00K | -1.37B | -1.07B | -7.0731 |
Tango Therapeutics Inc Stock (TNGX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-02-26 | Initiated | Canaccord Genuity | Buy |
| Feb-23-26 | Initiated | Mizuho | Outperform |
| Nov-18-25 | Initiated | Wolfe Research | Peer Perform |
| Aug-19-25 | Initiated | Piper Sandler | Overweight |
| Jul-17-24 | Initiated | Jefferies | Buy |
| Apr-04-24 | Initiated | Cantor Fitzgerald | Overweight |
| Feb-12-24 | Initiated | Piper Sandler | Overweight |
| Dec-08-23 | Initiated | B. Riley Securities | Buy |
| Oct-20-22 | Upgrade | H.C. Wainwright | Neutral → Buy |
| Sep-20-21 | Initiated | SVB Leerink | Outperform |
View All
Tango Therapeutics Inc Stock (TNGX) Latest News
Tango Therapeutics principal accounting officer sells $198k in stock By Investing.com - Investing.com Nigeria
Form 4 Tango Therapeutics Inc For: 24 September By Investing.com - Investing.com Nigeria
Under a trading plan, Tango Therapeutics (TNGX) officer Jessica Newcomb sold 8,200 shares in three transactions. - Stock Titan
TNGX Stock Hits All-Time High – Wolfe Research Calls Tango Therapeutic’s Pancreatic Cancer Trial Data ‘Groundbreaking’ - Stocktwits
Top Odyssey Therapeutics (ODTX) Competitors 2026 - MarketBeat
How Much Upside is Left in Tango Therapeutics (TNGX)? Wall Street Analysts Think 49.48% - Eastern Progress
Officer at Tango Therapeutics (NASDAQ: TNGX) to sell 15K shares - Stock Titan
CCORF Maintains Tango Therapeutics(TNGX.US) With Buy Rating, Maintains Target Price $46 - Moomoo
Why Is Tango Therapeutics (TNGX) Down 6.2% Since Last Earnings Report? - Yahoo Finance
Tango Therapeutics at cantor global healthcare: vopimetostat nears approval path - Investing.com India
TNGX Stock Crashes 20% After Reporting $0 Revenue In Q1 — But Analysts Still See Massive Upside - Stocktwits
Tango Therapeutics (TNGX) At 3.7x P B As Pullback Tests Whether It Looks Pricey - Yahoo Finance
Tango Therapeutics' R&D President Adam Crystal Executes Option Exercise and Sells 27,000 Shares Under Rule 10b5-1 Plan - Kalkine Media
Tango Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
Insider at Tango Therapeutics (TNGX) sells 27,000 shares in preset plan - Stock Titan
Tango Therapeutics to Participate in the 2026 Cantor Global Healthcare Conference - Yahoo Finance
Tango (TNGX) Results Check: Available Metrics Are Broadly in Line in the Current Update; Market Response: Shares Move 2.64% Higher on the DayROE Trend Analysis - careplusvn.com
Farallon Capital Management Adds to Tango Therapeutics (TNGX) St - GuruFocus
Tango Therapeutics appoints Robert Azelby to Board of Directors - scanx.trade
HC Wainwright Issues Pessimistic Outlook for TNGX Earnings - MarketBeat
Research Analysts Issue Forecasts for TNGX Q2 Earnings - MarketBeat
Trv Gp Iv LLC Makes New Investment in Tango Therapeutics, Inc. $TNGX - MarketBeat
Trv Gp Vi LLC Takes Position in Tango Therapeutics, Inc. $TNGX - MarketBeat
TANGO THERAPEUTICS, INC. : H.C. WAINWRIGHT RAISES TARGET PRICE TO $68 FROM $66 - Bitget
The Bull Case For Tango Therapeutics (TNGX) Could Change Following $400M ATM Offering And Leadership Shift - simplywall.st
Tango (TNGX) Earnings Numbers in Focus: The Headline Comparisons Are Near Their Estimates in the Current Update; Market Read: Shares Finish 0.59% Up for the Current SessionEPS Growth Report - Vinanet
Tango Therapeutics (NASDAQ:TNGX) Given New $68.00 Price Target at HC Wainwright - MarketBeat
H.C. Wainwright raises Tango Therapeutics price target to $68 By Investing.com - Investing.com Canada
H.C. Wainwright raises Tango Therapeutics price target to $68 - Investing.com
Stifel Maintains Tango Therapeutics(TNGX.US) With Buy Rating, Maintains Target Price $40 - Moomoo
Stifel reiterates Tango Therapeutics stock rating with $40 target - Investing.com
Stifel reiterates Tango Therapeutics stock rating with $40 target By Investing.com - Investing.com Canada
symbol__ Stock Quote Price and Forecast - CNN
Early trial shows strong pancreatic cancer resp... - Pluang
Tango Therapeutics: Promising Early Data, But A Long Road Ahead - Seeking Alpha
Walleye Capital LLC Makes New Investment in Tango Therapeutics, Inc. $TNGX - MarketBeat
Tango Therapeutics (NASDAQ:TNGX) Stock Rating Lowered by Wall Street Zen - MarketBeat
Tango Therapeutics (TNGX) investors report 0% beneficial ownership in latest 13G/A - Stock Titan
Tango Therapeutics (TNGX): TCG Crossover and Chen Yu disclose 7% beneficial stake - Stock Titan
Goldman Sachs Group (TNGX) discloses 6.0% beneficial stake in Tango Therapeutics - Stock Titan
Woodline holds 4.0M Tango Therapeutics (TNGX) shares, a 2.5% stake - Stock Titan
Farallon group discloses 16.27M Tango Therapeutics (TNGX) shares and warrants - Stock Titan
Handelsbanken Fonder AB Acquires Shares of 287,900 Tango Therapeutics, Inc. $TNGX - MarketBeat
Tango Therapeutics Insiders Selling US$727k In Stock Relieved As Market Cap Slides To US$4.4b - Moomoo
Tema ETFs LLC Buys New Holdings in Tango Therapeutics, Inc. $TNGX - MarketBeat
Tango Therapeutics (NASDAQ:TNGX): What Does the Latest Update Mean for Clinical Progress? - Kalkine Media
Analysts Offer Insights on Healthcare Companies: Tango Therapeutics (TNGX), Maze Therapeutics, Inc. (MAZE) and Xtant Medical Holdings (XTNT) - The Globe and Mail
Tango Therapeutics, Inc. (TNGX) Stock Price, News, Quote & History - Yahoo! Finance Canada
Tango Therapeutics Expands At-The-Market Equity Program - The Globe and Mail
Tango Therapeutics Inc (TNGX) News, Articles, Events & Latest Updates - Stocktwits
Adage Capital discloses 3.44% Tango Therapeutics (TNGX) stake in 13G/A filing - Stock Titan
Tango Therapeutics Inc Stock (TNGX) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.11%
1.87%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):